The assay was designed to detect all known variants of the virus that causes COVID-19, the company said. It received conditional approval from the New York State Department of Health in late December.
The sample collection kit enables the collection of own nasal swab specimens without supervision by medical personnel. Samples are mailed to Applied DNA Clinical Labs with results available in 24 to 48 hours, the company said.
Shares were down 1.5% in recent trading Friday.
Price: 3.90, Change: -0.01, Percent Change: -0.26
|Street Color: Global Calendar For Week Ending May 20|
|Ryder System Receives $4.4 Billion Cash Buyout Propo...|
|Payoneer Shares Rally After Q1 Beats Expectations, 2...|
|Market Chatter: Alibaba Group's Venture in Russia Re...|
|Research Alert: CFRA Raises View On Paycom Software ...|